U.S. markets open in 2 hours 37 minutes
  • S&P Futures

    3,768.00
    -26.00 (-0.69%)
     
  • Dow Futures

    30,133.00
    -177.00 (-0.58%)
     
  • Nasdaq Futures

    11,540.25
    -83.50 (-0.72%)
     
  • Russell 2000 Futures

    1,754.20
    -13.80 (-0.78%)
     
  • Crude Oil

    87.52
    -0.24 (-0.27%)
     
  • Gold

    1,722.70
    +1.90 (+0.11%)
     
  • Silver

    20.65
    +0.10 (+0.49%)
     
  • EUR/USD

    0.9880
    -0.0004 (-0.04%)
     
  • 10-Yr Bond

    3.7590
    0.0000 (0.00%)
     
  • Vix

    29.25
    +0.18 (+0.62%)
     
  • GBP/USD

    1.1251
    -0.0070 (-0.62%)
     
  • USD/JPY

    144.7470
    +0.1370 (+0.09%)
     
  • BTC-USD

    20,141.73
    +28.75 (+0.14%)
     
  • CMC Crypto 200

    457.62
    -0.79 (-0.17%)
     
  • FTSE 100

    7,019.79
    -32.83 (-0.47%)
     
  • Nikkei 225

    27,311.30
    +190.80 (+0.70%)
     

Strength Seen in Cytokinetics (CYTK): Can Its 11.5% Jump Turn into More Strength?

·2 min read

Cytokinetics CYTK shares soared 11.5% in the last trading session to close at $39.87. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 2.9% loss over the past four weeks.

The rise in share prices is likely attributable to positive investor expectations for Cytokinetics’ first-quarter 2021 results which are scheduled to be announced on May 4, after the closing bell.

This biopharmaceutical company is expected to post quarterly loss of $0.93 per share in its upcoming report, which represents a year-over-year change of -40.9%. Revenues are expected to be $5.12 million, down 21.8% from the year-ago quarter.

While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

For Cytokinetics, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on CYTK going forward to see if this recent jump can turn into more strength down the road.

The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

Cytokinetics is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, TELA Bio, Inc. TELA, finished the last trading session 0.4% higher at $9.26. TELA has returned -20.7% over the past month.

TELA Bio, Inc.'s consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.50. Compared to the company's year-ago EPS, this represents a change of +10.7%. TELA Bio, Inc. currently boasts a Zacks Rank of #4 (Sell).


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Cytokinetics, Incorporated (CYTK) : Free Stock Analysis Report
 
TELA Bio, Inc. (TELA) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research